Xu Ying, Dai Guo-Jing, Liu Qian, Liu Zhen-Li, Song Zhi-Qian, Li Li, Chen Wei-Heng, Lin Na
Institutes of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, P.R. China.
Basic Theory, China Academy of Chinese Medical Sciences, Beijing 100700, P.R. China.
Exp Ther Med. 2014 Oct;8(4):1065-1074. doi: 10.3892/etm.2014.1862. Epub 2014 Jul 24.
Sanmiao formula (SM) is a basic prescription for the treatment of gouty and rheumatoid arthritis that has been used in China over a long period of history. However, there is no evidence associating SM with the treatment of osteoarthritis (OA). In this study, a characterization of the anti-OA effect of SM was conducted using an rat model induced by anterior cruciate ligament transection and medial meniscus resection (ACLT plus MMx), together with studies using chondrocytes for further molecular characterization. Rats subjected to ACLT plus MMx were treated with SM at doses of 0.63, 1.25 and 2.5 g/kg per day for three or six weeks. SM treatment significantly inhibited the histopathological changes of articular cartilage damage and synovial inflammation in the rats following ACLT plus MMx. SM (2.5 g/kg) clearly inhibited chondrocyte apoptosis and prevented cartilage matrix degradation, which was indicated by the increased proteoglycan and collagen content, particularly with regard to type II collagen expression in articular cartilage. Furthermore, SM (2.5 g/kg) markedly inhibited the release of interleukin (IL)-1β, tumor necrosis factor-α and nitric oxide in serum, while simultaneously increasing the levels of bone morphogenetic protein-2 and transforming growth factor-β in the circulation. Notably, SM (2.5 g/kg) clearly attenuated the OA-augmented expression of matrix metalloproteinase (MMP)-13 and augmented the OA-reduced expression of tissue inhibitor of metalloproteinase (TIMP)-1 in the knee joints. In addition, SM significantly reduced the proportion of early and late apoptotic and sub-G phase cells, and clearly decreased the expression of MMP-13 and increased that of TIMP-1 at the mRNA and protein levels in IL-1β-induced chondrocytes. These findings provide the first evidence that SM effectively treats OA by inhibiting chondrocyte apoptosis, cartilage matrix degradation and the inflammatory response.
三妙方(SM)是一种在中国长期用于治疗痛风性和类风湿性关节炎的基础方剂。然而,尚无证据表明SM可用于治疗骨关节炎(OA)。在本研究中,使用前交叉韧带横断和内侧半月板切除诱导的大鼠模型(ACLT加MMx)对SM的抗OA作用进行了表征,并使用软骨细胞进行了进一步的分子表征研究。对接受ACLT加MMx的大鼠每天给予0.63、1.25和2.5 g/kg剂量的SM,持续三或六周。SM治疗显著抑制了ACLT加MMx后大鼠关节软骨损伤和滑膜炎症的组织病理学变化。SM(2.5 g/kg)明显抑制软骨细胞凋亡并防止软骨基质降解,这表现为蛋白聚糖和胶原蛋白含量增加,特别是关节软骨中II型胶原蛋白的表达。此外,SM(2.5 g/kg)显著抑制血清中白细胞介素(IL)-1β、肿瘤坏死因子-α和一氧化氮的释放,同时增加循环中骨形态发生蛋白-2和转化生长因子-β的水平。值得注意的是,SM(2.5 g/kg)明显减弱了OA增强的基质金属蛋白酶(MMP)-13的表达,并增强了OA降低的膝关节中金属蛋白酶组织抑制剂(TIMP)-1的表达。此外,SM显著降低了早期和晚期凋亡细胞及亚G期细胞的比例,并在IL-1β诱导的软骨细胞中明显降低了MMP-13的mRNA和蛋白质水平的表达并增加了TIMP-1的表达。这些发现提供了首个证据,表明SM通过抑制软骨细胞凋亡、软骨基质降解和炎症反应有效治疗OA。